David Einhorn - DME Capital Management
Holding/activity history for Talis Biomedical Corp (TLIS)
← All TLIS superinvestors
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2024 Q3 | 0 | 0.00 | Sell 100.00% | 0.06 | SEC | ||
| 2024 Q2 | 149,052 | 0.06 | $8.66 | $1,291,059 | SEC | ||
| 2024 Q1 | 149,052 | 0.06 | $8.75 | $1,304,205 | SEC | ||
| 2023 Q4 | 149,052 | 0.05 | $7.45 | $1,110,437 | SEC | ||
| 2023 Q3 | 149,052 | 0.05 | Reduce 93.33% | 0.05 | $5.77 | $860,030 | SEC |
| 2023 Q2 | 2,235,783 | 0.05 | $0.48 | $1,073,176 | SEC | ||
| 2023 Q1 | 2,235,783 | 0.06 | $0.49 | $1,095,534 | SEC | ||
| 2022 Q4 | 2,235,783 | 0.07 | $0.45 | $996,488 | SEC | ||
| 2022 Q3 | 2,235,783 | 0.11 | $0.68 | $1,524,000 | SEC | ||
| 2022 Q2 | 2,235,783 | 0.14 | $0.81 | $1,816,000 | SEC | ||
| 2022 Q1 | 2,235,783 | 0.20 | Add 42.47% | 0.06 | $1.41 | $3,152,000 | SEC |
| 2021 Q4 | 1,569,300 | 0.36 | Buy | 0.36 | $4.01 | $6,293,000 | SEC |